Farhad Vahid | Breast Cancer | Editorial Board Member

Published on 03/12/202503/12/2025 by Oncology

Dr. Farhad Vahid | Breast Cancer | Editorial Board Member

Assistance Professor | Luxembourg Institute of Health | Luxembourg

Dr. Farhad Vahid is a prominent researcher at the Luxembourg Institute of Health, Strassen, specializing in nutritional epidemiology, diet-related cardiometabolic health, and public health interventions. His research focuses on understanding the impact of dietary patterns, inflammatory indices, antioxidants, and nutrient intake on chronic diseases, including cardiovascular risk, obesity, breast cancer, and reproductive health. Dr. Vahid has contributed to advancing population-based and clinical research through large cohort studies, randomized clinical trials, and systematic reviews, providing evidence for the development of diet quality indices and population health guidelines. His work emphasizes the intersection of nutrition, chronic disease prevention, and healthy aging, with translational implications for both individual and public health outcomes. Over his career, he has demonstrated strong collaborative engagement, working with multidisciplinary teams across international institutions to address global health challenges through diet and lifestyle interventions. Dr. Vahid’s publications, including studies on dietary carotenoids, the dietary inflammatory index, cardiovascular risk factors, and healthy aging, have informed both scientific understanding and practical public health strategies. His research not only contributes to academic knowledge but also has significant societal impact by guiding nutritional recommendations and interventions aimed at reducing chronic disease burden and promoting population health. Dr. Vahid’s academic influence and research productivity are reflected in his metrics 1,529 citations, 100 documents, and an h-index of 22.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

Vahid, F., Zand, H., Nosrat–Mirshekarlou, E., Najafi, R., & Hekmatdoost, A. (2015). The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: A review. Gene, 562(1), 8–15. Cited by 237.

Vahid, F., Shivappa, N., Hekmatdoost, A., Hebert, J. R., Davoodi, S. H., & Sadeghi, M. (2017). Association between maternal dietary inflammatory index (DII) and abortion in Iranian women and validation of DII with serum concentration of inflammatory factors: Case-control study. Applied Physiology, Nutrition, and Metabolism, 42(5), 511–516. Cited by 110.

Ashkar, F., Rezaei, S., Salahshoornezhad, S., Vahid, F., Gholamalizadeh, M., & [others]. (2020). The role of medicinal herbs in treatment of insulin resistance in patients with polycystic ovary syndrome: A literature review. Biomolecular Concepts, 11(1), 57–75. Cited by 96.

Vahid, F., Shivappa, N., Faghfoori, Z., Khodabakhshi, A., Zayeri, F., & Hebert, J. R. (2018). Validation of a dietary inflammatory index (DII) and association with risk of gastric cancer: A case-control study. Asian Pacific Journal of Cancer Prevention: APJCP, 19(6), 1471. Cited by 92.

Vahid, F., Shivappa, N., Karamati, M., Naeini, A. J., Hebert, J. R., & Davoodi, S. H. (2017). Association between dietary inflammatory index (DII) and risk of prediabetes: A case-control study. Applied Physiology, Nutrition, and Metabolism, 42(4), 399–404. Cited by 85.

Xin Yi Foong | Breast Cancer | Best Researcher Award

Published on 02/12/202502/12/2025 by Oncology

Ms. Xin Yi Foong | Breast Cancer | Best Researcher Award

Core Surgical Trainee | Mid Yorkshire Teaching NHS Trust | United Kingdom

Dr Xin Yi Foong is a clinical researcher in Plastic and Reconstructive Surgery whose academic work is centred on improving the safety, accuracy, and reliability of autologous breast reconstruction through quantitative imaging and evidence-based microsurgical innovation. Her research explores the use of indocyanine green (ICG) fluorescence imaging to guide intraoperative evaluation of mastectomy flap perfusion, with particular emphasis on establishing objective perfusion scoring methods that support consistent, data-guided surgical decisions. Her published study in the Journal of Plastic, Reconstructive & Aesthetic Surgery introduced a structured quantitative perfusion algorithm that demonstrated strong discriminatory capability in identifying poorly perfused tissue and informing reconstructive planning, offering evidence that aligns with national quality frameworks and enhances postoperative outcomes. Alongside this work, she is investigating postoperative monitoring strategies in DIEP flap reconstruction, assessing early-phase observation models that preserve patient safety while promoting efficient and clinically coherent perioperative pathways. Her wider academic activity includes outcome audits, service-improvement initiatives, and reconstructive pathway analyses, all aimed at refining surgical workflows through quantitative measures, imaging-based assessment, and rigorous postoperative metrics. Conducted within multidisciplinary teams of plastic surgeons, anaesthetists, and breast specialists, her research supports the translation of imaging-derived insights into routine clinical practice. Through a growing publication profile, an active ORCID research identity, and sustained commitment to scientifically grounded surgical advancement, Dr Foong contributes to the development of reproducible, clinically meaningful, and patient-centred innovations that strengthen microsurgical dependability and elevate the overall quality of care within reconstructive breast surgery.

Profiles: Scopus | ORCID

Featured Publications

1. Foong, X. Y., Williamson, A., Lymperopoulos, N., & Holmes, W. J. M. (2025). Does indocyanine green imaging perfusion scoring reduce mastectomy flap necrosis in immediate autologous breast reconstruction? A single-centre cohort study. Journal of Plastic, Reconstructive & Aesthetic Surgery, 111, 198–206.

2. Foong, X. Y., Williamson, A., Lymperopoulos, N., & Holmes, W. J. M. (2025). Does intraoperative indocyanine green (ICG) reduce the outcome of mastectomy skin flap necrosis in patients undergoing immediate breast reconstruction? European Journal of Surgical Oncology. Advance online publication.

Gerardo Rosati | Breast Cancer | Best Researcher Award

Published on 27/11/202527/11/2025 by Oncology

Dr. Gerardo Rosati | Breast Cancer | Best Researcher Award

Azienda Ospedaliera San Carlo di Potenza | Italy

Dr. Gerardo Rosati is a distinguished Italian medical oncologist whose career reflects over three decades of sustained clinical practice, research leadership, and commitment to advancing evidence-based cancer care. Laureato con lode all’Università “Federico II” di Napoli e successivamente specializzato in Oncologia presso la Seconda Università di Napoli, ha sviluppato precocemente un interesse scientifico per i markers tumorali e per l’innovazione terapeutica nei tumori solidi. La sua formazione è stata arricchita da numerose borse di studio FIRC, ESO e Fondazione Lina Belli, che gli hanno consentito di partecipare a corsi avanzati internazionali su colon-retto, neuro-oncologia, recidive ginecologiche, terapia antalgica e strategie emergenti in oncologia medica. Dal 1998 opera stabilmente presso l’U.O. di Oncologia Medica dell’Azienda Ospedaliera “S. Carlo” di Potenza, dove ha assunto ruoli via via più qualificati fino alla responsabilità del coordinamento dell’attività di ricerca clinica. La sua attività come sperimentatore in oltre cento studi clinici di fase I–III e in numerosi progetti osservazionali riguarda chemioterapie innovative, farmaci biologici, anti-EGFR, anti-angiogenici, immunoterapia, tossicità correlate ai trattamenti e biomarcatori predittivi. Ha inoltre svolto un’intensa attività di revisione scientifica per riviste internazionali e per enti accademici e sanitari nazionali, contribuendo al miglioramento della qualità metodologica della ricerca oncologica. Membro attivo di AIOM, ESMO ed ESO College, promuove l’integrazione tra clinica, ricerca e formazione, con un impatto significativo sui percorsi assistenziali nei tumori gastrointestinali e in altre neoplasie solide. His academic influence is reflected in 2,813 citations, 123 documents, and an h-index of 27, underscoring his meaningful contributions to contemporary clinical oncology.

Profiles: Scopus | ORCID

Featured Publications

1. Rosati, G., De Stefano, A., Restivo, A., Fanotto, V., Cicero, G., Colombo, A., Dell’Aquila, E., Parisi, A., Ortolani, S., Lutrino, S. E., Carlomagno, C., Dapoto, F., Reggiardo, G., Tonetto, F., Ravo, V., Aprile, G., Bilancia, D., Avallone, A., Romano, C., Argiolas, V., & Giovinazzo, G. (2026). Short-Course Radiotherapy for Older Patients with Locally Advanced Rectal Cancer and Unfit for Chemotherapy: The SOFT Study. Radiotherapy and Oncology.

2. Rosati, G., Piccirillo, M. C., Nasti, G., De Stefano, A., Carlomagno, C., Romano, C., Cassata, A., Silvestro, L., Nappi, A., Perrone, F., Budillon, A., & Avallone, A. (2025). A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study. Drugs & Aging, 1–10.

3. Avallone, A., Giuliani, F., De Stefano, A., Santabarbara, G., Nasti, G., Montesarchio, V., Rosati, G., Cassata, A., Leo, S., Romano, C., Tamburini, E., Silvestro, L., Lotesoriere, C., Nappi, A., Santini, D., Petrillo, A., Colombo, A., Febbraro, A., Leone, A., Mannavola, F., & Laterza, M. M. (2024). Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. Journal of Clinical Oncology, 43(7), 829–839.

4. Montrone, M., Rosati, G., Longo, V., Catino, A., Massafra, R., Nardone, A., Pesola, F., Montagna, E. S., Marech, I., & Pizzutilo, P. (2023). Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. Journal of Clinical Medicine, 12(5), 1833.

5. Rosati, G., Montrone, M., Pacilio, C., Colombo, A., Cicero, G., Paragliola, F., Vaia, A., Annunziata, L., & Bilancia, D. (2022). An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer. Journal of Clinical Medicine, 11(23), 7108.

Aminah Alotaibi | Breast Cancer | Best Researcher Award

Published on 30/10/202530/10/2025 by Oncology

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.

Hongyu li | Breast Cancer | Best Researcher Award

Published on 03/05/202503/05/2025 by Oncology

Hongyu li | Breast Cancer | Best Researcher Award

Xinjiang medical university | China

AUTHOR PROFILE

SCOPUS

🎓EARLY ACADEMIC PURSUITS

Assoc. Prof. Dr. Hongyu Li embarked on her academic journey at Xinjiang Medical University, where she earned her Doctor of Medicine degree and subsequently completed a Ph.D. in 2021. Her formative years were marked by rigorous academic training and an early interest in the oncology of breast diseases, which laid the foundation for her future specialization in breast cancer metastasis research.

👩‍🏢PROFESSIONAL ENDEAVORS

Currently serving as an Associate Professor, Associate Chief Physician, and Doctor of Medicine at the Department of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Dr. Li brings over a decade of clinical expertise to the field. Her clinical focus is on the early detection, diagnosis, and management of breast cancer. She has been honored with prestigious awards including the “Tianchi Talent” Youth Doctor Award (2022), the Outstanding Postdoctoral Special Funding (2023), and was selected for the “789 Talent” Training Program (2024), cementing her reputation as a High-Level Talent and Outstanding Young Physician.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER

Dr. Li’s scientific inquiry is anchored in understanding the molecular mechanisms of breast cancer metastasis, with a specific focus on breast cancer brain metastasis (BCBM)—a critical and poorly understood manifestation associated with poor prognosis. Her translational research bridges clinical challenges and bench-side investigations, aiming to identify novel biomarkers and potential therapeutic targets for BCBM.

She adopts an integrative approach that translates clinical observations into mechanistic questions, enhancing the effectiveness of future treatments and diagnostic strategies for late-stage breast cancer.

📚IMPACT AND INFLUENCE

Dr. Li’s work is contributing to shaping the clinical paradigms in breast cancer care within the Xinjiang region and beyond. Her research is improving understanding of metastatic processes, especially in underrepresented ethnic populations. She is also involved in institutional collaborations and has served in editorial capacities, reinforcing her influence in both academic and clinical oncology spheres.

💪LEGACY AND FUTURE CONTRIBUTIONS

Looking forward, Dr. Li aims to establish a dedicated translational research unit focused on metastatic breast cancer, particularly BCBM. She is committed to mentoring young researchers and expanding interdisciplinary collaborations that bridge molecular oncology with precision medicine. Her ultimate goal is to redefine treatment algorithms and enhance survival outcomes for patients with advanced-stage breast cancer.

🌍CONCLUSION

Assoc. Prof. Dr. Hongyu Li stands as a beacon of translational oncology, seamlessly integrating clinical care with cutting-edge research. Her relentless pursuit of knowledge, commitment to public health, and strategic focus on a critically unmet need in oncology make her a deserving nominee for the Best Researcher Award.